Trandolapril/verapamil
< Trandolapril
| Combination of | |
|---|---|
| Trandolapril | Calcium channel blocker |
| Verapamil | ACE inhibitor |
| Clinical data | |
| Trade names | Tarka |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Trandolapril/verapamil (Tarka) is an oral antihypertensive medication that combines a slow release formulation of verapamil hydrochloride, a calcium channel blocker, and an immediate release formulation of trandolapril, an ACE inhibitor. The patent, held by Abbott Laboratories, expired on February 24, 2015.
This combination medication contains angiotensin-converting enzyme (ACE) inhibitor and calcium channel blocker and is prescribed for high blood pressure.